JAC Advance Access originally published online on January 14, 2003
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2003) 51, 347-352
© 2003 The British Society for Antimicrobial Chemotherapy
Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections
Rega Institute and Laboratory of Microbiology, University Hospital Gasthuisberg, Catholic University of Leuven, Leuven, Belgium
Received 18 September 2002; returned 23 October 2002; revised 25 November 2002; accepted 26 November 2002
Objectives: To determine susceptibility rates and patterns in Pseudomonas aeruginosa strains isolated from nosocomial infections.
Methods: Seven hundred and sixteen P. aeruginosa isolates from 40 different hospitals in Belgium and the Grand Duchy of Luxembourg were collected in 1999.
Results: Resistance rates varied significantly between hospitals. Of the fluoroquinolones, ciprofloxacin showed least resistance (24%), levofloxacin showed 27.5% resistance and ofloxacin 37.5%. Of the aminoglycosides, amikacin was the most potent antibiotic (10.5% resistance), followed by isepamicin (12%), tobramycin (19.5%) and gentamicin (23.5%). Of the ß-lactam antibiotics, meropenem was the most active (9.5% resistance); piperacillin and piperacillin/tazobactam had, respectively, 24% and 17.5% resistance, ceftazidime 28.5%, cefepime 29.5%, ticarcillin/clavulanic acid 37% and aztreonam 55.5%. MIC distribution curves show the presence of significant subpopulations, with MICs just below breakpoint for many antibiotics.
Conclusion: Resistance of P. aeruginosa to penicillins, cephalosporins, fluoroquinolones and aminoglycosides varies between hospitals, but is increasing.
Keywords: Pseudomonas aeruginosa, nosocomial infections, susceptibility rates, surveillance
* Tel: +32-16-34-79-02; Fax: +32-16-34-79-31; E-mail: johan.vaneldere{at}uz.kuleuven.ac.be
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
N. Aoki, K. Tateda, Y. Kikuchi, S. Kimura, C. Miyazaki, Y. Ishii, Y. Tanabe, F. Gejyo, and K. Yamaguchi Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa J. Antimicrob. Chemother., March 1, 2009; 63(3): 534 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. S. Kaye, Z. A. Kanafani, A. E. Dodds, J. J. Engemann, S. G. Weber, and Y. Carmeli Differential Effects of Levofloxacin and Ciprofloxacin on the Risk for Isolation of Quinolone-Resistant Pseudomonas aeruginosa. Antimicrob. Agents Chemother., June 1, 2006; 50(6): 2192 - 2196. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hocquet, P. Nordmann, F. El Garch, L. Cabanne, and P. Plesiat Involvement of the MexXY-OprM Efflux System in Emergence of Cefepime Resistance in Clinical Strains of Pseudomonas aeruginosa. Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1347 - 1351. [Abstract] [Full Text] [PDF] |
||||
![]() |
Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 388 - 416. [Full Text] [PDF] |
||||
![]() |
K. Poole Aminoglycoside Resistance in Pseudomonas aeruginosa Antimicrob. Agents Chemother., February 1, 2005; 49(2): 479 - 487. [Full Text] [PDF] |
||||


